Search Results

Biotech Bay

UPDATE: Predicine Introduces PredicineCARE™ NGS Kit for Tumor Profiling

Predicine, Inc., a leading molecular insights company, announced the release of its innovative PredicineCARE™ NGS Kit.

April 11, 2024

·

2 min read

Biotech Bay

Predicine Introduces PredicineCARE™ NGS Kit for Global Clinical Trials, CDx Development and Patient Testing

Predicine, Inc., a leading molecular insights company, announced the release of its innovative PredicineCARE™ NGS Kit.

April 5, 2024

·

2 min read

Biotech Bay

Predicine to Present 15 Liquid Biopsy Studies at AACR 2024

Predicine, Inc. A leading precision oncology company, announced that it will present data from 15 ctDNA studies at AACR 2024, spotlighting the clinical utility of Predicine’s genomic and epigenomic liquid biopsy solutions for patient selection, disease monitoring, and disease mechanism studies.

April 5, 2024

·

3 min read

Business

Predicine Announces Collaboration with Apollomics to Develop PredicineCARE™ as a Companion Diagnostic Assay in Lung Cancer

Predicine, Inc., a leading molecular insights company, announced a collaboration with Apollomics, Inc.

April 5, 2024

·

2 min read

Business

Predicine Announces Collaboration with Janssen to Develop PredicineCARE™ as a Companion Diagnostic Assay in Localized Bladder Cancer

Predicine, Inc., a leading molecular insights company, announced a collaboration with Janssen Pharmaceutica NV, a Johnson & Johnson company.

January 8, 2024

·

2 min read

Biotech Bay

Predicine announces six studies showcasing MRD and liquid biopsy innovations at ESMO 2023

Predicine, a pioneer in the liquid biopsy, announce its participation in the European Society for Medical Oncology (ESMO) 2023 Congress in Madrid, Spain.

October 17, 2023

·

2 min read

Biotech Bay

Predicine to Introduce PredicineALERT™ MRD Assay and Present Twelve Posters at AACR 2023 Conference

Predicine, a global molecular insights company, announced that it will present data from 12 studies and introduce PredicineALERT™, a next-generation Minimal Residual Disease liquid biopsy assay at the 2023 AACR Conference on April 14-19, 2023.

April 14, 2023

·

3 min read

Biotech Bay

Predicine to Introduce PredicineALERT™ MRD Assay and Present Two ctDNA Studies in Genitourinary Cancers at AUA 2023 Annual Meeting

Predicine announced that it will present two studies and introduce PredicineALERT™ Minimal Residual Disease liquid biopsy assay to genitourinary cancers at the 2023 American Urological Association Annual Meeting held in Chicago between April 28 to May 1, 2023.

April 28, 2023

·

2 min read

Biotech Bay

Predicine to Present Four Studies at 2023 ASCO Genitourinary (GU) Symposium Highlighting the Technical and Clinical Utility of Predicine’s Liquid Biopsy Based Assays

Predicine, a global molecular insights company, is committed to advancing genitourinary cancer detection and treatment decisions through its proprietary non-invasive next-generation sequencing assays.

February 16, 2023

·

2 min read

Drug Development

Predicine Announces New Study Published in The New England Journal of Medicine Demonstrating Clinical Utility of its MRD Liquid Biopsy Assay in Supporting Genentech’s Phase 1 Clinical Trial of Divarasib

Predicine, Inc., a pioneer in the field of liquid biopsy, announced a new study published in The New England Journal of Medicine, demonstrating the clinical utility of its minimal residual disease Liquid Biopsy Assay in support of Genentech’s Phase 1 Clinical Trial of Divarasib.

September 20, 2023

·

3 min read